AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38127151 — intervention group
Group type: EXPERIMENTAL
Intervention: Red meat consumption
Number of subjects: 403
Study 38127188 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg
Number of subjects: 272
Study 38127188 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg
Number of subjects: 272
Study 38127188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 38127212 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Number of subjects: 99
Study 38127335 — intervention group
Group type: EXPERIMENTAL
Intervention: BEEP followed by WBRT
Number of subjects: 118
Study 38127335 — intervention group
Group type: COMPARATOR
Intervention: WBRT alone
Number of subjects: 118
Study 38127464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucus plugs in proximal airway generations
Number of subjects: 57
Study 38127464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucus plugs in larger proximal generations
Number of subjects: 57
Study 38127464 — intervention group
Group type: EXPERIMENTAL
Intervention: Model of airflow resistance due to mucus plugs
Number of subjects: 57
Study 38127487 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 120
Study 38127487 — intervention group
Group type: COMPARATOR
Intervention: Cediranib
Number of subjects: 120
Study 38127487 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib and Cediranib
Number of subjects: 120
Study 38127508 — intervention group
Group type: EXPERIMENTAL
Intervention: FATIGUEWALK (FaW) plus treatment as usual (TAU)
Number of subjects: 428
Study 38127508 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU) alone
Number of subjects: 428
Study 38127545 — intervention group
Group type: EXPERIMENTAL
Intervention: Arterial lactate index measurement
Number of subjects: 0
Study 38127545 — intervention group
Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 38127586 — intervention group
Group type: EXPERIMENTAL
Intervention: Emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks
Number of subjects: 55
Study 38127722 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib-Blinatumomab protocol
Number of subjects: 0
Study 38127780 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus abiraterone
Number of subjects: 796
Study 38127780 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus abiraterone
Number of subjects: 796
Study 38127845 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent stress
Number of subjects: 0
Study 38127845 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic stress
Number of subjects: 0
Study 38127845 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 cases
Number of subjects: 0
Study 38127974 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane (ESP) block
Number of subjects: 60
Study 38127974 — intervention group
Group type: COMPARATOR
Intervention: Infrainguinal fascia iliaca compartment (FIC) block
Number of subjects: 60
Study 38128008 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection during pregnancy
Number of subjects: 2300
Study 38128008 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening tests for neurodevelopment and other health outcomes
Number of subjects: 2300
Study 38128008 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood specimens for SARS-CoV-2 antibody testing
Number of subjects: 2300
Study 38128154 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (16-week open-label trial)
Number of subjects: 161
Study 38128154 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SGK1 expression and hippocampal volume
Number of subjects: 161
Study 38128401 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver emotional reactions at pretreatment
Number of subjects: 82
Study 38128401 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver emotional reactions at mid-treatment
Number of subjects: 82
Study 38128401 — intervention group
Group type: EXPERIMENTAL
Intervention: Child PTS at mid-treatment
Number of subjects: 82
Study 38128402 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation
Number of subjects: 336
Study 38128402 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness and gratitude
Number of subjects: 336
Study 38128402 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of behavioral activation and mindfulness
Number of subjects: 336
Study 38128402 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 336
Study 38128414 — intervention group
Group type: EXPERIMENTAL
Intervention: PepGNP-Dengue (low dose)
Number of subjects: 26
Study 38128414 — intervention group
Group type: EXPERIMENTAL
Intervention: PepGNP-Dengue (high dose)
Number of subjects: 26
Study 38128414 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-GNP (low dose)
Number of subjects: 26
Study 38128414 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-GNP (high dose)
Number of subjects: 26
Study 38128414 — intervention group
Group type: EXPERIMENTAL
Intervention: PepGNP-Dengue (both doses)
Number of subjects: 26
Study 38128460 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO; 40,000 IU/ml)
Number of subjects: 59
Study 38128460 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 59
Study 38128556 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNTA (200 units)
Number of subjects: 200
Study 38128556 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 200
Study 38128649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile MOUD programs providing same-day access to MOUD
Number of subjects: 11
Study 38128649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile MOUD programs
Number of subjects: 11
Study 38128724 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (specific antibiotics not detailed)
Number of subjects: 24
Study 38128731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-uterine tamponnement balloon
Number of subjects: 332
Study 38128731 — intervention group
Group type: COMPARATOR
Intervention: Severe PPH
Number of subjects: 332
Study 38128731 — intervention group
Group type: EXPERIMENTAL
Intervention: Low hemoglobin values during severe PPH management
Number of subjects: 332
Study 38128733 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nut consumption
Number of subjects: 28
Study 38128934 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% atropine eye drop once nightly bilaterally for 1 year
Number of subjects: 150
Study 38128934 — intervention group
Group type: COMPARATOR
Intervention: Placebo eye drop once nightly bilaterally for 1 year
Number of subjects: 150
Study 38129103 — intervention group
Group type: EXPERIMENTAL
Intervention: Orointestinal microbiome
Number of subjects: 424
Study 38129103 — intervention group
Group type: EXPERIMENTAL
Intervention: Classifier for severity with 16 different species and systemic inflammatory response syndrome
Number of subjects: 424
Study 38129103 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional pathway units from GSEA
Number of subjects: 424
Study 38129116 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction training (LL-BFRT) at 30% 1-repetition maximum (1-RM) with 70% arterial occlusion pressure
Number of subjects: 30
Study 38129116 — intervention group
Group type: COMPARATOR
Intervention: High-load strength training (HL-ST) at 70% 1-RM
Number of subjects: 30
Study 38129117 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 240 mg
Number of subjects: 249
Study 38129117 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 160 mg
Number of subjects: 249
Study 38129117 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept 80 mg
Number of subjects: 249
Study 38129117 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 38129117 — intervention group
Group type: EXPERIMENTAL
Intervention: Telitacicept and Placebo
Number of subjects: 249
Study 38129136 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 806
Study 38129136 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab alone
Number of subjects: 806
Study 38129357 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 331
Study 38129357 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 331
Study 38129525 — intervention group
Group type: EXPERIMENTAL
Intervention: Berzosertib with radiotherapy (RT) at six dose levels (highest dose 240 mg/m)
Number of subjects: 34
Study 38129525 — intervention group
Group type: EXPERIMENTAL
Intervention: Berzosertib with cisplatin and capecitabine
Number of subjects: 34
Study 38129527 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized reaching training restricted to the spasticity-free elbow range
Number of subjects: 46
Study 38129527 — intervention group
Group type: COMPARATOR
Intervention: Non-personalized reaching training
Number of subjects: 46
Study 38129599 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant cannula
Number of subjects: 15
Study 38129599 — intervention group
Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 15
Study 38129731 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed IgG 20% 0.4 g/kg
Number of subjects: 24
Study 38129731 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed IgG 20% 1.0 g/kg
Number of subjects: 24
Study 38129731 — intervention group
Group type: EXPERIMENTAL
Intervention: Unwarmed IgG 20% 1.0 g/kg
Number of subjects: 24
Study 38129775 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured lifestyle and compensatory aid intervention
Number of subjects: 225
Study 38129775 — intervention group
Group type: COMPARATOR
Intervention: Education-only self-guided intervention
Number of subjects: 225
Study 38129778 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain elastography (SE) after one and two cycles of NAC
Number of subjects: 122
Study 38129778 — intervention group
Group type: EXPERIMENTAL
Intervention: Strain elastography (SE) imaging features
Number of subjects: 122
Study 38129794 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-based markers and MRI assessments including Muscle Assessment Score, portal flow assessment, magnet resonance elastography, and abbreviated MRI for HCC screening.
Number of subjects: 150
Study 38129794 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of lifestyle, muscular strength, physical performance, body composition, and quality of life.
Number of subjects: 150
Study 38129794 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal evolution of biomarkers.
Number of subjects: 150
Study 38129868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (INT) received an average of eight intervention sessions (50-90 min) over 6 months
Number of subjects: 337
Study 38129868 — intervention group
Group type: COMPARATOR
Intervention: Control group (TAU)
Number of subjects: 337
Study 38129868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (INT)
Number of subjects: 337
Study 38129896 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented exercise (12 weeks, 3×60-min per week)
Number of subjects: 0
Study 38129896 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized resistance and aerobic exercise (12 weeks, 3×60-min per week)
Number of subjects: 0
Study 38129896 — intervention group
Group type: COMPARATOR
Intervention: Stretching control (12 weeks, 3×60-min per week)
Number of subjects: 0
Study 38129910 — intervention group
Group type: EXPERIMENTAL
Intervention: Real sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Number of subjects: 32
Study 38129910 — intervention group
Group type: COMPARATOR
Intervention: Sham sensorimotor transcranial stimulation (PAS) with robot-assisted therapy
Number of subjects: 32
Study 38130041 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.92 mg with SSRI/SNRI
Number of subjects: 2257
Study 38130041 — intervention group
Group type: COMPARATOR
Intervention: Ozanimod 0.92 mg without SSRI/SNRI
Number of subjects: 2257
Study 38130330 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNS)
Number of subjects: 0
Study 38130330 — intervention group
Group type: COMPARATOR
Intervention: Iron and folic acid (IFA)
Number of subjects: 0
Study 38130375 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine plus exercise (supervised treadmill walking 3 times weekly, duloxetine starting at 30 mg daily titrating to 60 mg daily)
Number of subjects: 9
Study 38130375 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine plus exercise
Number of subjects: 9
Study 38130409 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoliflodacin plus doxycycline combination therapy
Number of subjects: 0
Study 38130409 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38130645 — intervention group
Group type: EXPERIMENTAL
Intervention: QL0911 (1 μg/kg subcutaneously once weekly for 24 weeks, adjusted to maintain platelet counts from 50 × 10^9/L to 200 × 10^9/L)
Number of subjects: 216
Study 38130645 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneously once weekly for 24 weeks)
Number of subjects: 216
Study 38130799 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital SPA (digital intervention for pediatric chronic pain)
Number of subjects: 0
Study 38130916 — intervention group
Group type: COMPARATOR
Intervention: Mepolizumab
Number of subjects: 105
Study 38130916 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analogue Scales (VAS)
Number of subjects: 105
Study 38131034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration of 8 hours per day
Number of subjects: 2689
Study 38131034 — intervention group
Group type: EXPERIMENTAL
Intervention: Long sleep duration (>8 hours per day)
Number of subjects: 2689
Study 38131034 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoglobin
Number of subjects: 2689
Study 38131034 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood urea nitrogen (BUN)
Number of subjects: 2689
Study 38131034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-density lipoprotein cholesterol (HDL-c)
Number of subjects: 2689
Study 38131181 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavior therapy (Exp-CBT)
Number of subjects: 274
Study 38131181 — intervention group
Group type: COMPARATOR
Intervention: Traditional cognitive behavior therapy (T-CBT)
Number of subjects: 274
Study 38131294 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant stereotactic body radiotherapy (SBRT) plus adebrelimab and chemotherapy
Number of subjects: 13
Study 38131617 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib maintenance therapy
Number of subjects: 103
Study 38131621 — intervention group
Group type: EXPERIMENTAL
Intervention: famciclovir 500 mg twice daily for 12 weeks
Number of subjects: 30
Study 38131621 — intervention group
Group type: COMPARATOR
Intervention: natalizumab treatment (before famciclovir)
Number of subjects: 30
Study 38131628 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy (including systemic therapy or chemoradiation)
Number of subjects: 0
Study 38131628 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 0
Study 38131628 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 0
Study 38133080 — intervention group
Group type: EXPERIMENTAL
Intervention: Tongue electrical impedance myography (EIM)
Number of subjects: 4
Study 38133155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg plus standard of care for up to 14 days
Number of subjects: 500
Study 38133155 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 500
Study 38133156 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support (telerounds from Monday to Friday, specialists available, continuing education activities)
Number of subjects: 1600
Study 38133156 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine support
Number of subjects: 1600
Study 38133156 — intervention group
Group type: COMPARATOR
Intervention: Usual care in pediatric intensive care unit
Number of subjects: 1600
Study 38133554 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selgantolimod 1.5 mg once weekly for 24 weeks
Number of subjects: 48
Study 38133554 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selgantolimod (3 mg or 1.5 mg)
Number of subjects: 48
Study 38133554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 38133554 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral selgantolimod (up to 3 mg)
Number of subjects: 48
Study 38133600 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEPTECH (telehealth intervention)
Number of subjects: 229
Study 38133600 — intervention group
Group type: COMPARATOR
Intervention: Control (access to an online listing of PrEP resources)
Number of subjects: 229
Study 38133601 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAA) related HCV cure
Number of subjects: 9735
Study 38133601 — intervention group
Group type: COMPARATOR
Intervention: Unhealthy alcohol use
Number of subjects: 9735
Study 38133639 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 60 µg coadministered with dTpa
Number of subjects: 5
Study 38133639 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 120 µg coadministered with dTpa
Number of subjects: 5
Study 38133639 — intervention group
Group type: COMPARATOR
Intervention: dTpa coadministered with placebo
Number of subjects: 5
Study 38133639 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 120 µg (second vaccination)
Number of subjects: 5
Study 38133639 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 (both doses)
Number of subjects: 5
Study 38133806 — intervention group
Group type: EXPERIMENTAL
Intervention: mCLIP Partial Prosthesis
Number of subjects: 72
Study 38133825 — intervention group
Group type: EXPERIMENTAL
Intervention: Malnutrition diagnosed using GLIM criteria at 7 weeks after treatment initiation
Number of subjects: 238
Study 38133825 — intervention group
Group type: EXPERIMENTAL
Intervention: High scores for nutrition impact symptoms (NIS) assessed by the Head and Neck Patient Symptom Checklist
Number of subjects: 238
Study 38133914 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily sublingual 17-β estradiol
Number of subjects: 100
Study 38133914 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily sublingual 17-β estradiol
Number of subjects: 100
Study 38133914 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17-β estradiol
Number of subjects: 100
Study 38133914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (as antiandrogen)
Number of subjects: 100
Study 38133914 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid panel, homeostatic model assessment for insulin resistance, coagulation factors II, IX, and XI, Von Willebrand factor, activated protein C resistance, protein C, and protein S
Number of subjects: 100
Study 38133925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 16
Study 38134037 — intervention group
Group type: EXPERIMENTAL
Intervention: automated directly observed therapy-conditional economic incentive (aDOT-CEI) intervention
Number of subjects: 0
Study 38134037 — intervention group
Group type: EXPERIMENTAL
Intervention: aDOT-CEI intervention
Number of subjects: 0
Study 38134126 — intervention group
Group type: EXPERIMENTAL
Intervention: Live with Wearable Monitoring Device program from trained community health workers
Number of subjects: 0
Study 38134126 — intervention group
Group type: COMPARATOR
Intervention: Wearable monitoring device only
Number of subjects: 0
Study 38134136 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral active transauricular nerve stimulation
Number of subjects: 36
Study 38134136 — intervention group
Group type: COMPARATOR
Intervention: Sham transauricular nerve stimulation
Number of subjects: 36
Study 38134231 — intervention group
Group type: EXPERIMENTAL
Intervention: Flortaucipir PET measures in former football players (PRO+COL)
Number of subjects: 218
Study 38134231 — intervention group
Group type: EXPERIMENTAL
Intervention: Flortaucipir PET measures in former players over 60 years old
Number of subjects: 218
Study 38134231 — intervention group
Group type: COMPARATOR
Intervention: Flortaucipir PET measures for TES groups
Number of subjects: 218
Study 38134254 — intervention group
Group type: COMPARATOR
Intervention: Step Activity Monitoring (SAM)
Number of subjects: 250
Study 38134254 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Walking (FAST)
Number of subjects: 250
Study 38134254 — intervention group
Group type: COMPARATOR
Intervention: Combined Intervention (FAST+SAM)
Number of subjects: 250
Study 38134265 — intervention group
Group type: EXPERIMENTAL
Intervention: QSM (Quantitative Susceptibility Mapping)
Number of subjects: 143
Study 38134265 — intervention group
Group type: EXPERIMENTAL
Intervention: DCEQP (Dynamic Contrast-Enhanced Quantitative Perfusion)
Number of subjects: 143
Study 38134260 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic COVID-19 (AS-COVID)
Number of subjects: 15124
Study 38134260 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic COVID-19 (S-COVID)
Number of subjects: 15124
Study 38134260 — intervention group
Group type: COMPARATOR
Intervention: COVID-negative controls
Number of subjects: 15124
Study 38134268 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral cavernous malformation patients with symptomatic hemorrhage (SH)
Number of subjects: 123
Study 38134268 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline modified Rankin Scale score of 1
Number of subjects: 123
Study 38134268 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline National Institutes of Health Stroke Scale score of 0 to 4
Number of subjects: 123
Study 38134268 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional outcomes and patient-reported outcomes
Number of subjects: 123
Study 38134268 — intervention group
Group type: EXPERIMENTAL
Intervention: Score changes as a marker for hemorrhage
Number of subjects: 123
Study 38134305 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring trachoma transmission with antibody data; estimated median IgG half-life of 3 years; seroreversion rate of 2.5 per 100 person-years (95% CI, 1.6-3.5)
Number of subjects: 0
Study 38134484 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral nerve block with 100 mg of ropivacaine
Number of subjects: 50